Ulf Brasen

Title: Ulf Brasen: Innovator in Dextran Sulfate Research

Introduction

Ulf Brasen is a notable inventor based in Quarteira, Portugal. He has made significant contributions to the field of biomedical research, particularly in the development of dextran sulfate compounds. With a total of two patents to his name, Brasen's work focuses on methods to treat and prevent blood-mediated inflammatory reactions.

Latest Patents

Ulf Brasen's latest patents include innovative methods involving dextran sulfate. The first patent describes methods of treating, inhibiting, and/or preventing instant blood-mediated inflammatory reaction (IBMIR) through the administration of dextran sulfate. This compound is characterized by a number average molecular weight (M) measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da. It also features an average sulfate number per glucose unit within an interval of 2.5 and 3.0, and an average sulfation of the C2 position in the glucose units of at least 90%. The second patent focuses on a dextran sulfate or a salt thereof, which also has a number average molecular weight (Mn) within the same range and improved biological effects compared to similar molecules available on the market.

Career Highlights

Ulf Brasen is currently associated with Tx Medic AB, where he continues to advance his research in dextran sulfate. His work has the potential to significantly impact the treatment of inflammatory conditions, showcasing his dedication to innovation in the biomedical field.

Collaborations

Ulf Brasen collaborates with Lars M Bruce, contributing to the advancement of their shared research interests.

Conclusion

Ulf Brasen's contributions to dextran sulfate research highlight his role as an innovator in the biomedical field. His patents reflect a commitment to improving treatment methods for inflammatory reactions, marking him as a significant figure in his area of expertise.